Long non-coding RNA (lncRNA) five prime to Xist (FTX) promotes retinoblastoma progression by regulating the microRNA-320a/with-no-lysine kinases 1 (WNK1) axis

References

• Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol. 2016;31(2):227–236.
   PubMed Web of Science ®Google Scholar
• Rao R, Honavar SG. Retinoblastoma. The Indian Journal of Pediatrics. 2017;84(12):937–944.
   PubMed Web of Science ®Google Scholar
• Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68(11):2356–2365.
   PubMed Web of Science ®Google Scholar
• Jathar S, Kumar V, Srivastava J, et al. Technological developments in lncRNA biology. Adv Exp Med Biol. 2017;1008:283–323.
   PubMed Web of Science ®Google Scholar
• Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839(11):1097–1109.
   PubMed Web of Science ®Google Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol. 2016;1402:271–286.
   PubMedGoogle Scholar
• Ye J, Li J, Zhao P. Roles of ncRNAs as ceRNAs in gastric cancer. Genes (Basel). 2021;12(7):1036.
   Web of Science ®Google Scholar
• Ergun S, Oztuzcu S. Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways. Tumour Biol. 2015;36:3129–3136.
   PubMedGoogle Scholar
• He X, Chai P, Li F, et al. A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3. Mol Cancer. 2020;19(1):115.
   PubMed Web of Science ®Google Scholar
• Xu C, Tian LH. LncRNA XIST promotes proliferation and epithelial-mesenchymal transition of retinoblastoma cells through sponge action of miR-142-5p. Eur Rev Med Pharmacol Sci. 2020;24:9256–9264.
   PubMed Web of Science ®Google Scholar
• Chureau C, Chantalat S, Romito A, et al. Ftx is a non-coding RNA which affects Xist expression and chromatin structure within the X-inactivation center region. Hum Mol Genet. 2011;20:705–718.
   PubMed Web of Science ®Google Scholar
• Zhao K, Ye Z, Li Y, et al. LncRNA FTX contributes to the progression of colorectal cancer through regulating miR-192-5p/EIF5A2 axis. Onco Targets Ther. 2020;13:2677–2688.
   PubMed Web of Science ®Google Scholar
• Huang S, Zhu X, Ke Y, et al. LncRNA FTX inhibition restrains osteosarcoma proliferation and migration via modulating miR-320a/TXNRD1. Cancer Biol Ther. 2020;21(4):379–387.
   PubMed Web of Science ®Google Scholar
• He X, Sun F, Guo F, et al. Knockdown of long noncoding RNA FTX inhibits proliferation, migration, and invasion in renal cell carcinoma cells. Oncol Res. 2017;25(2):157–166.
   PubMed Web of Science ®Google Scholar
• Xing Y, Wen X, Ding X, et al. CANT1 lncRNA triggers efficient therapeutic efficacy by correcting aberrant lncing cascade in malignant uveal melanoma. Mol Ther. 2017;25(5):1209–1221.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang Z, Gao M, et al. lncRNA MALAT1 regulated ATAD2 to facilitate retinoblastoma progression via miR-655-3p. Open Med (Wars). 2021;16(1):931–943.
   PubMedGoogle Scholar
• Yuan X, Sun Z, Cui C. Knockdown of lncRNA HOTTIP inhibits retinoblastoma progression by modulating the miR-101-3p/STC1 axis.  Technol Cancer Res Treat. 2021;20:1533033821997831.
   Google Scholar
• Sun X, Shen H, Liu S, et al. Long noncoding RNA SNHG14 promotes the aggressiveness of retinoblastoma by sponging microRNA‑124 and thereby upregulating STAT3. Int J Mol Med. 2020;45:1685–1696.
   PubMed Web of Science ®Google Scholar
• Tan Q, Tan Z, Liu J, et al. Integrated bioinformatic analysis of competing endogenous RNA network of choriocarcinoma. Med Sci Monit. 2021;27:e931475.
   PubMed Web of Science ®Google Scholar
• Wan W, Wan W, Long Y, et al. MiR-25-3p promotes malignant phenotypes of retinoblastoma by regulating PTEN/Akt pathway. Biomed Pharmacothe. 2019;118:109111.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Orbach DB, VanderVeen D. Retinoblastoma. Pediatr Clin North Am. 2015;62(1):201–223.
   PubMed Web of Science ®Google Scholar
• Mendoza PR, Grossniklaus HE. Therapeutic options for retinoblastoma. Cancer Control. 2016;23(2):99–109.
   PubMed Web of Science ®Google Scholar
• Li X, Zhao Q, Qi J, et al. lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARγ pathway in hepatocellular carcinoma. Int J Oncol. 2018;53:551–566.
   PubMed Web of Science ®Google Scholar
• Jiang W, Zhang B, Sun J, et al. LncRNA FTX promotes the tumorigenesis of lung adenocarcinoma by targeting miR-300. Panminerva Med. 2020. DOI:10.23736/s0031-0808.19.03823-0.
   Google Scholar
• F Zhang, X-S Wang, B Tang, et al. Long non-coding RNA FTX promotes gastric cancer progression by targeting miR-215. Eur Rev Med Pharmacol Sci. 2020;24:3037–3048.
   PubMed Web of Science ®Google Scholar
• Goodall GJ, Wickramasinghe VO. RNA in cancer. 2021;21:22–36.
   Google Scholar
• Chen GQ, Liao ZM, Liu J, et al. LncRNA FTX promotes colorectal cancer cells migration and invasion by miRNA-590-5p/RBPJ axis.  Biochem Genet. 2021;59:560–573.
   Google Scholar
• Chen H, Liu T, Ouyang H, et al. Upregulation of FTX promotes osteosarcoma tumorigenesis by increasing SOX4 expression via miR-214-5p. Onco Targets Ther. 2020;13:7125–7136.
   PubMed Web of Science ®Google Scholar
• Huo X, Wang H, Huo B, et al. FTX contributes to cell proliferation and migration in lung adenocarcinoma via targeting miR-335-5p/NUCB2 axis. Cancer Cell Int. 2020;20:89.
   Google Scholar
• Fu G, Lu J, Zheng Y, et al. MiR-320a inhibits malignant phenotype of melanoma cells via targeting PBX3. J B.U.ON. 2020;25:2071–2077.
   Google Scholar
• Ge X, Cui H, Zhou Y, et al. miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep. 2017;16(6):9664–9670.
   PubMed Web of Science ®Google Scholar
• Li H, Yu L, Liu J, et al. miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients. Oncotarget. 2017;8(12):19723–19737.
   PubMedGoogle Scholar
• Kong L, Sun Y, Chen M, et al. Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3. Exp Ther Med. 2020;20:9.
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207.
   PubMed Web of Science ®Google Scholar
• Selvan LDN, Danda R, Madugundu AK. Phosphoproteomics of retinoblastoma: a pilot study identifies aberrant kinases. Molecules. 2018;23. DOI:10.3390/molecules23061454.
   Google Scholar
• Caterina Costa, Paola Indovina, Eliseo Mattioli, et al. P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. Cell Death Dis. 2020;11:748.
   Google Scholar
• Xie N, Jia Z, Li L. miR‑320a upregulation contributes to the development of preeclampsia by inhibiting the growth and invasion of trophoblast cells by targeting interleukin 4. Mol Med Rep. 2019;20:3256–3264.
   PubMed Web of Science ®Google Scholar
• Yao Kong, Zhi-Kui Nie, Feng Li, et al. MiR-320a was highly expressed in postmenopausal osteoporosis and acts as a negative regulator in MC3T3E1 cells by reducing MAP9 and inhibiting PI3K/AKT signaling pathway. Exp Mol Pathol. 2019;110:104282.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu H, Shao J, et al. miR-320a serves as a negative regulator in the progression of gastric cancer by targeting RAB14. Mol Med Rep. 2017;16(3):2652–2658.
   PubMed Web of Science ®Google Scholar